期刊文献+

他汀治疗对冠状动脉慢血流患者血清可溶性E-选择素、hs-CRP水平的影响 被引量:5

Effect of statins therapy on serum levels of soluble E-selectin and high sensitive C-reactive protein in patients with slow coronary flow
下载PDF
导出
摘要 目的:了解较长时间的他汀治疗对冠状动脉慢血流(SCF)患者血清可溶性E-选择素(SES)以及高敏C反应蛋白(hs-CRP)水平的影响,评价他汀类药物在SCF患者治疗中的地位。方法:30例SCF患者,术后规范化服用常规剂量的他汀类药物治疗6个月,对患者治疗前后的血清低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、SES、hsCRP水平进行比较分析。结果:他汀治疗6个月后,SCF患者血清LDL-C[(3.48±2.03)mmol/L vs(2.59±1.91)mmol/L,P<0.05]、SES[(58.60±3.96)ng/mL vs(48.31±2.89)ng/mL,P<0.05]以及hs-CRP[(3.92±0.40)μg/mL vs(2.97±0.42)μg/mL,P<0.05]水平明显降低,HDL-C水平有一定程度的升高[(0.90±0.23)mmol/L vs(1.01±0.18)mmol/L,P>0.05]。结论:他汀治疗可明显降低SCF患者低强度炎症反应因子血清SES以及hs-CRP水平。 Objective : To understand the effect of long term statins therapy on serum levels of high sensitive C-reactive protein (hs-CRP) and soluble E-selectin (SES) in patients with slow coronary flow (SCF). Methods : Thirty patients with SCF were treated with routine dose of statins drugs for 6 months. The patientslow density lipoprotein-eholesterol (LDL-C), high density lipoprotein-eholesterol (HDL-C) , serum levels of hs-CRP and SES were compared and analyzed after 6 months follow-up. Results : The serum levels of LDL-C [ ( 3.48 ± 2.03 ) mmoL/L vs ( 2.59 ± 1.91 ) mmoL/L, P 〈 0.05 ], SES [ (58.60 ±3.96) ng/mL vs (48.31±2.89) ng/mL, P 〈0.05 ] and hs-CRP [ (3.92 ±0.40) μg/mL vs (2.97 ±0.42) μg/mL, P 〈 0. 05 ] were reduced significantly after 6 months statins therapy. The serum level of HDL-C somewhat increased [ ( 0.90 ±0.23 ) mmol/L vs ( 1.01 ± 0.18 ) mmol/L ,P 〉 0.05 ]. Conclusion : Statins therapy can significantly reduce the serum levels of the low grade inflammatory response factors hs-CRP and SES in patients with SCF.
机构地区 武汉市第一医院
出处 《内科急危重症杂志》 2014年第5期313-314,共2页 Journal of Critical Care In Internal Medicine
基金 武汉市卫生局资助课题(No:2010WX10C05)
关键词 冠状动脉慢血流 SES hs-CRP 他汀 Coronary slow flow Soluble E-selectin High sensitive C-reactive protein Statins
  • 相关文献

参考文献12

  • 1Baykan M, Baykan EC,Turan S, et al. Assessment of left ventricular function and Tel index by tissue doppler imaging in patients with slow coronary flow [ J]. Echoeardiography ,2009,26 ( 10 ) : 1167-1172.
  • 2Sen T. Coronary slow flow phenomenon leads to ST elevation myocar- dial infarction[ J]. Korean Circ J,2013,43 (3) : 196-198.
  • 3Yoon HJ, Jeong MH, Cho SH, et al. Endothelial dysfunction and in- creased carotid intima-media thickness in the patients with slow coro- nary flow[J]. J Korean Med Sci,2012,27(6) : 6144518.
  • 4贺立群,雷健,王顺,李佐民,昌薇,柯于鹤,邓次妮,张帆,文飞,冷沁,郑蓉,陈海云,欧阳银娥.冠状动脉慢血流患者血清E-选择素与高敏C反应蛋白水平的变化[J].内科急危重症杂志,2013,19(6):348-349. 被引量:3
  • 5Turhan H, Saydam GS, Erbay AR. et al. Increased plasma soluble adhe- sion molecules; ICAM-1 ,VCAM-1 ,and E-sdectin levels in patients with slow coronary flow[J]. Int J Cardiol,2006,108 (2) : 224-230.
  • 6Erdogan T, Canga A, Kocaman SA, et al. Increased epicardial adipose tissue in patients with slow coronary flow phenomenon [ J ]. Kardiol Pol,2012,70(9) :903-909.
  • 7Cmlga A, Cetin M, Kocaman SA, et al. Increased serum resistin levels in patients with coronary slow-flow phenomenon [ J ]. Herz, 2013,38 (7) :773-778.
  • 8Li JJ, Zheng X, Li J. Statins may be beneficial for patients with slow coronary flow syndrome due to its anti-inflammatory property[ J]. Med Hypotheses, 2007,69 ( 2 ) : 333 -337.
  • 9Fan Y,Yang SS, Yu JB, et al. Atorvastatin use and coronary flow re- serve in patients with coronary slow flow [ J ]. Zhonghua Xin Xue Guan Bing Za Zhi,2010,38 (2) :143-146.
  • 10Cakmak M, Tanriverdi H, Cakmak N, et al. Simvastatin may improve myocardial perfusion abnormality in slow coronaty flow [ J ]. Cardialo- gy,2008,110(1) :39-44.

二级参考文献8

  • 1Goel PK,Gupta SK,Agarwal A. et al. Slow coronary flow: a distinct angio-graphic subgroup in syndrome X[J]. Angiology,2001,52(8) : 507-514.
  • 2Baykan M, Baykan EC, Turan S. et al. Assessment of left ventricularfunction and Tei index by tissue doppler imaging in patients with slowcoronary flow[ J]. Echocardiography,2009,26 (10) :1167-1172.
  • 3Sen T. Coronary slow flow phenomenon leads to ST elevation myocar-dial infarction[ J]. Korean Circ J,2013 ,43(3 ) : 196-198.
  • 4Mangieri E, Macchiarelli G, Ciavolella M, et al. Slow coronary flow :clinical and histopathological features in patients with otherwise nor-mal epicardial coronary arteries[ J] . Cathet Cardiovasc Diagn,J996,37(4) :375-381.
  • 5Tanriverdi H,Evrengul H,Mergen H,et al. Early sign of atherosclero-sis in slow coronary flow and relationship with angiotensin-convertingenzyme I/D polymorphism[ J]. Heart Vessels,2007 ,22( 1 ) :1-8.
  • 6Turhan H, Saydam GS, Erbay AR. et al. Increased plasma soluble ad-hesion molecules ; ICAM-1 , VCAM-1,and E-selectin levels in patientswith slow coronary flow[ J]. Int J Cardiol,2006,108(2) :224-230.
  • 7Pekdemir H, Cin VG, Cicek D. et al. Slow coronary flow may be a signof diffuse atherosclerosis. Contribution of FFR and IVUS [ J ]. ActaCardiol,2004,59(2) :127-133.
  • 8Madak N, Nazli Y,Mergen H. et al. Acute phase reactants in patientswith coronary slow flow phenomenon [ J ]. Anadolu Kardiyol Derg,2010,10(5) :416420.

共引文献2

同被引文献55

  • 1汤森,闫静,徐文喜.孟鲁司特治疗慢性阻塞性肺疾病急性加重期60例的疗效观察[J].中国医学前沿杂志(电子版),2014,6(3):75-77. 被引量:7
  • 2Rezkalla SH, Kloner RA. Coronary no-reflow phenomenon:from the experimental laboratory to the cardiac catheterization laboratory [ J ]. Catheter Cardiovasc Interv ,2008,72 (7) :950-957.
  • 3Niccoli G, Burzotta F, Galiuto L, et al. Myocardial no-reflow in humans [J]. J Am Coil Cardiol,2009,54(4) :281-292.
  • 4Su Q, Nyi TS, Li L. Adenosine and verapamil for no-reflow during pri- mary pereutaneous coronary intervention in people with acute myocar- dial infarction[ J]. Cochrane Database Syst Rev ,2015,5 :CD009503.
  • 5vant Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban[ J]. Drugs,2009,69 ( 1 ) :85-100.
  • 6Vant Hof AW,Ten Berg J, Heestemamas T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty ( On-TIME 2) : a muhicentre, double-blind, random- ised controlled trial[J]. Lancet,2008,372(9638) :537-546.
  • 7Niccoli G, Cosentino N,Spaziani C, et al. New strategies for the man- agement of no-reflow after primary percutaneous coronary intervention [ J ]. Expert Rev Cardiovasc Ther ,2011,9 ( 5 ) :615-630.
  • 8Shakerian F,Sanati H,Kiani R,et al. Comparison of outcomesof diseased coronary arteries ectasia, stenosis and combined[ J ].Res Cardiovasc Med, 2015 , 4(1): 25206.
  • 9Karaagac K, Yontar OC, Tenekecioglu E,et al. Evaluation of Tp-Te interval and Tp - Te/QTc ratio in patients with coronary ar-tery ectasia[Jj. Int J Clin Exp Med,2014 ,7(9) : 2865 - 2870.
  • 10Sultana R,Sultana N,Ishaq M, et al. The prevalence and clinicalprofile of angiographic coronary ectasia [ J ]. J Pak Med Assoc,2011,61(4) :372 -375.

引证文献5

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部